Tekmira Pharmaceuticals Corp Price Target Raised to $16.00 at Maxim Group (TKMR)
Maxim Group upped their target price on shares of Tekmira Pharmaceuticals Corp (NASDAQ:TKMR) from $9.00 to $16.00 in a research note issued on Monday, Analyst Ratings Network.com reports. The firm currently has a “buy” rating on the stock. Maxim Group’s price objective points to a potential upside of 79.37% from the stock’s previous close.
Tekmira Pharmaceuticals Corp (NASDAQ:TKMR) opened at 8.92 on Monday. Tekmira Pharmaceuticals Corp has a 52-week low of $3.46 and a 52-week high of $9.65. The stock’s 50-day moving average is $6.05 and its 200-day moving average is $5.17.
Tekmira is a leader in the development of therapeutic agents based upon Nobel Prize winning breakthroughs in the field of gene silencing, known as RNA interference (NASDAQ:TKMR).
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.